This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

Analyst actions and earnings marred a few health stocks on a largely flat Friday for the sector ahead of a holiday weekend.

BioScrip (BIOS - Get Report) was trading up 41 cents, or 6.7%, at $6.58 after Broadpoint Capital upgraded the stock to buy from neutral.

"In our view, BIOS shares are cheap by nearly any measure. Acute downward pressure on the shares seems unwarranted, as we expect 4Q:07 results to reflect a continuation of recent financial and operations progress," wrote Broadpoint's Glenn Garmont in a note to investors on Friday.

Also falling, Vision-Sciences (VSCI) announced that it reached an agreement with Pentax, resolving pending disputes and dismissing all related legal proceedings over pricing, volume and delivery schedules for items supplied by Pentax. It's also delaying of the filing and release of its third-quarter earnings, and release of its results for the first nine months of fiscal 2008, due to the recent resignation of the company's newly-hired controller.

Shares were trading down 77 cents, or 19.6%, at $3.16.

Elsewhere, American Medical Systems (AMMD) suffered a downgrade Friday but was trading up $1.61, or 12.2%, at $14.81. On Thursday post-close the company reported a fourth-quarter loss after a profit in the year-ago period but beat analyst expectations on an adjusted basis excluding legal and technology licensing charges.

American Medical expects to earn between 84 cents and 99 cents a share on an adjusted basis, on revenue of between $500 million and $520 million for 2008, while analysts polled by Thomson Financial were looking for 69 cents a share on $522.8 million. RBC Capital downgraded the stock to sector perform from outperform on Friday.

More earnings: Drug ingredient company Cambrex (CBM - Get Report) saw shares dip 5% to $9.90 Friday after it announced that it swung to a profit but missed earnings expectations Thursday post close.

The company earned $780,000, or 3 cents a share, on revenue of $69.8 million, vs. a loss of $25.4 million, or 94 cents a share, in the year-prior period. Analysts surveyed by Thomson Financial predicted 13 cents a share on revenue of $67 million.

Ultrasound device company SonoSite (SONO) said its fourth-quarter earnings were marred by expenses. The company earned $4.3 million, or 25 cents a share, down from $5.8 million, or 34 cents a share, in the year-ago period. SonoSite reported quarterly revenue of $64.8 million, vs. $54.4 million in 2006.

Profit fell shy of the Thomson Financial consensus target of 30 cents a share on revenue of $63.7 million. And shares declined $2.89, or 8.2%, to $32.04, Friday.

Biopharmaceutical company Xenoport (XNPT - Get Report) also saw shares fall Friday after its Thursday post-close earnings release. The company reported net income of $2.5 million, or 9 cents a share, vs. a loss of $18.6 million, or 76 cents a share, in the year-ago quarter. Revenue in the recent quarter was positively affected by upfront and milestone payments from GlaxoSmithKline (GSK), Astellas Pharma and Xanodyne Pharmaceuticals, increasing to $25.8 million from $3.1 million in the year-ago quarter.

Shares were down $3.40, or 5.6%, at $57.11. The stock is a component of the Nasdaq biotechnology index, which was down 8.62, or 1%, at 793.96.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIOS $2.20 9.70%
CBM $52.78 3.40%
XNPT $6.38 -0.86%
VSCI $1.59 10.42%
AAPL $118.03 -0.71%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs